ReviewCancer medicine2022

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer.

Javier Martínez-TruferoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.